Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7785-7793

  Nyman, David W ^b   Campbell, Kimberley J ^b   Hersh, Evan ^b   Long, Kristen ^b   Richardson, Kelly ^b   Trieu, Vuong ^b   Desai, Neil ^b   Hawkins, Michael J ^b   Von Hoff, Daniel D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANASTROZOLE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; FUROSEMIDE; GEMCITABINE; HYDROXYCHLOROQUINE; METHOTREXATE; NANOPARTICLE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RICINOMACROGOL; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; ALBUMINOID; ANTINEOPLASTIC AGENT; NANOMATERIAL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPENDENT EDEMA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUID RETENTION; HUMAN; HYPERSENSITIVITY; LUNG CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; ONYCHOLYSIS; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISUAL ACUITY; VOMITING; CANCER STAGING; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NANOSTRUCTURES; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 32944481043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.6148     Document Type: Article

References (37)

1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
2. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
3. Chu E, DeVita VT: Physicians' Cancer Chemotherapy Drug Manual 2003. Sudbury, MA, Jones and Bartlett Publishers, 2002, p 284
4. Crown J, O'Leary M: The taxanes: An update. Lancet 355:1176-1178, 2000
5. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
6. Kloover JS, den Bakker MA, Gelderblom H, et al: Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br J Cancer 90:304-305, 2004
7. ten Tije AJ, Verweij J, Loos WJ, et al: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685, 2003
8. Sparreboom A, Scripture CD, Trieu V, et al: Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:41364243, 2005
9. Winer E, Berry D, Duggan D, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 22:2061-2068, 2004
10. Gelderblom H, Verweij J, Nooter K, et al: Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598, 2001
11. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
12. Abraxis Oncology: Abraxane: Prescribing information. Schaumburg, IL, Abraxis Oncology, a Division of American Pharmaceutical Partners, Inc, 2005
13. Vorum H: Reversible ligand binding to human serum albumin: Theoretical and clinical aspects. Dan Med Bull 46:379-399, 1999
14. John TA, Vogel SM, Tiruppathi C, et al: Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2841187-L196, 2003
15. Minshall RD, Sessa WC, Stan RV, et al: Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 285:L1179-L1183, 2003
16. Tiruppathi C, Song W, Bergenfeldt M, et al: Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 272:25968-25975, 1997
17. Porter PL, Sage EH, Lane TF, et al: Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43:791-800, 1995
18. Kim YW, Park Y-K, Lee J, et al: Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13:652-657, 1998
19. Thomas R, True LD, Bassuk JA, et al: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6:1140-1149, 2000
20. Brown TJ, Shaw PA, Karp X, et al: Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75:25-33, 1999
21. Paley PJ, Goff BA, Gown AM, et al: Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78:336-341, 2000
22. Ledda F, Bravo AI, Adris S, et al: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108:210-214, 1997
23. Massi D, Franchi A, Borgognoni L, et al: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30:339-344, 1999
24. Yamanaka M, Kanda K, Li NC, et al: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 166:2495-2499, 2001
25. Yamashita K, Upadhay S, Mimori K, et al: Clinical significance of secreted protein acidic and rich in cysteine in esophageal carcinoma and its relation to carcinoma progression. Cancer 97:2412-2419, 2003
26. Rempel SA, Ge S, Gutierrez JA: SPARC: A potential diagnostic marker of invasive meningiomas. Clin Cancer Res 5:237-241, 1999
27. Schnitzer JE, Oh P: Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol 263: H1872-H1879, 1992
28. Tiruppathi C, Finnegan A, Malik AB: Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells. Proc Natl Acad Sci U S A 93:250-254, 1996
29. Schilling U, Friedrich EA, Sinn H, et al: Design of compounds having enhanced tumour uptake, using serum albumin as a carrier: Part II. In vivo studies. Int J Rad Appl Instrum B 19:685-695, 1992
30. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
31. Nabholtz J-M, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
32. Gradishar WJ, Tjulandin S, Davidson N, et al: Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 23:7794-7803, 2005
33. Tolcher AW, Eckhardt SG, Kuhn J, et al: Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 19:2937-2947, 2001
34. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
35. Ibrahim NK, Samuels B, Page R, et al: Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-6026, 2005
36. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
37. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003